Featured Research

from universities, journals, and other organizations

Drug delays onset of pain and quality of life deterioration for prostate cancer

Date:
September 24, 2013
Source:
University of North Carolina School of Medicine
Summary:
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

The study, published Sept. 24 in Lancet Oncology, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers measured the pain and quality of life impact of abiraterone acetate, an orally prescribed treatment marketed under the trade name Zytiga, when administered to 1,088 patients with metastatic castration-resistant prostate cancer at 151 sites in the U.S., Europe, Canada and Australia. The randomized trial enrolled patients who had experienced little or no pain at the outset, prescribing abiraterone acetate and prednisone to 546 of the enrollees and placebo plus prednisone to the remainder.

"The majority of men with metastatic prostate cancer experience pain that is often debilitating and can have a profound impact on their ability to function, sleep, work, and their enjoyment of life. Pain is a central problem in prostate cancer and managing pain remains a major challenge," said Dr. Basch.

The design of the study emphasized the importance of patient reported-outcomes in evaluating new treatments. In previous publications, Dr. Basch has shown the importance of evaluating how treatments impact how people feel and function during drug development.

"Patients with cancer experience many symptoms related to their disease and to drug side effects, but this information is generally neither measured rigorously in clinical trials nor included in U.S. drug labels. As a result, patients often have incomplete information about how they may expect to feel with a new therapy. This study addresses this information gap towards better-informed decisions," said Dr. Basch.

Abiraterone acetate was approved by the Food and Drug Administration (FDA) in 2011. The drug, which was found to increase survival in patients by an average of four months, is in routine clinical use in the United States and Europe.

The study tracked the progression of pain intensity, the time until patients needed opiates to control pain, and patients' quality of life using validated questionnaires. Patients reported their pain intensity on a scale of one to 10 as well as the amount that pain interfered with their sleep, mood and ability to conduct daily activities via the Brief Pain Inventory.

The combination of abiraterone acetate and prednisone significantly prolonged the time until clinically meaningful worsening of pain intensity as well as quality of life deterioration compared to patients receiving the placebo and prednisone. Patients reported a more than eight-month delay in progression of pain, and a more than four-month delay in quality of life deterioration. Significant improvements were also seen in how pain interferes with daily activities, and time until opiate use.

Pain is a significant predictor of overall survival, and the ability to delay suffering represents a meaningful clinical benefit to patients, according to Dr. Basch. The delay of pain also allows patients to forgo the use of opiates and other pain medications for longer periods, a benefit since those medications also cause negative side effects that deteriorate quality of life.

"The design of this study provides a path forward for future research to utilize patient-centered endpoints," said Dr. Basch. "Not only does it provide essential information about the properties of abiraterone acetate, but it demonstrates the feasibility of rigorously measuring symptoms in a large multi-national study. It also helps identify areas of needed future methodological research."


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ethan Basch, Karen Autio, Charles J Ryan, Peter Mulders, Neal Shore, Thian Kheoh, Karim Fizazi, Christopher J Logothetis, Dana Rathkopf, Matthew R Smith, Paul N Mainwaring, Yanni Hao, Thomas Griffin, Susan Li, Michael L Meyers, Arturo Molina, Charles Cleeland. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet Oncology, 2013; DOI: 10.1016/S1470-2045(13)70424-8

Cite This Page:

University of North Carolina School of Medicine. "Drug delays onset of pain and quality of life deterioration for prostate cancer." ScienceDaily. ScienceDaily, 24 September 2013. <www.sciencedaily.com/releases/2013/09/130924193522.htm>.
University of North Carolina School of Medicine. (2013, September 24). Drug delays onset of pain and quality of life deterioration for prostate cancer. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/09/130924193522.htm
University of North Carolina School of Medicine. "Drug delays onset of pain and quality of life deterioration for prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2013/09/130924193522.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins